[go: up one dir, main page]

EA200701211A1 - Полипептиды, которые связываются с br3, и их применение - Google Patents

Полипептиды, которые связываются с br3, и их применение

Info

Publication number
EA200701211A1
EA200701211A1 EA200701211A EA200701211A EA200701211A1 EA 200701211 A1 EA200701211 A1 EA 200701211A1 EA 200701211 A EA200701211 A EA 200701211A EA 200701211 A EA200701211 A EA 200701211A EA 200701211 A1 EA200701211 A1 EA 200701211A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
binding
application
methods
relates
Prior art date
Application number
EA200701211A
Other languages
English (en)
Inventor
Кристин М. Амброуз
Мерседес Балаж
Лаура Дефордж
Марк С. Деннис
Жермен Фу
Стефен Д. Херст
Чинвэй В. Ли
Генри Б. Лоуман
Флавиус Мартин
Джеральд Р. Накамура
Дхайя Сешасайи
Мелисса Старовасник
Джеффри С. Томпсон
Original Assignee
Дженентек, Инк.
Байоджен Айдек Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк., Байоджен Айдек Ма Инк. filed Critical Дженентек, Инк.
Publication of EA200701211A1 publication Critical patent/EA200701211A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)

Abstract

Настоящее изобретение относится к новым BR3-связывающим антителам и полипептидам, включающим антагонистические и агонистические полипептиды. Настоящее изобретение также относится к использованию BR3-связывающих антител и полипептидов, например, в способах лечения, скрининга, диагностики, в методах тестирования и очистки белков.
EA200701211A 2004-12-31 2005-12-23 Полипептиды, которые связываются с br3, и их применение EA200701211A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64032304P 2004-12-31 2004-12-31
PCT/US2005/047072 WO2006073941A2 (en) 2004-12-31 2005-12-23 Polypeptides that bind br3 and uses thereof

Publications (1)

Publication Number Publication Date
EA200701211A1 true EA200701211A1 (ru) 2007-12-28

Family

ID=36588679

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701211A EA200701211A1 (ru) 2004-12-31 2005-12-23 Полипептиды, которые связываются с br3, и их применение

Country Status (14)

Country Link
US (2) US20080181888A1 (ru)
EP (1) EP1838735A2 (ru)
JP (1) JP2008526205A (ru)
KR (1) KR20070107687A (ru)
CN (1) CN101120021A (ru)
AP (1) AP2007004034A0 (ru)
AU (1) AU2005323025A1 (ru)
BR (1) BRPI0518994A2 (ru)
CA (1) CA2595112A1 (ru)
EA (1) EA200701211A1 (ru)
IL (1) IL183353A0 (ru)
MX (1) MX2007008017A (ru)
NO (1) NO20072721L (ru)
WO (1) WO2006073941A2 (ru)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
WO2007086994A1 (en) * 2005-11-15 2007-08-02 Balyasnikova Irina V Single chain fragment of monoclonal antibody 9b9 and uses thereof
DK1948798T3 (en) * 2005-11-18 2015-07-06 Glenmark Pharmaceuticals Sa The anti-alpha2-integrin antibodies and uses thereof
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2008098145A1 (en) * 2007-02-07 2008-08-14 University Of Washington Methods for modulating antigen-specific b cell responses
WO2008100805A2 (en) * 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
NZ583318A (en) 2007-07-16 2012-07-27 Genentech Inc Humanized anti-cd79b antibodies and immunoconjugates and methods of use
CN111499748A (zh) 2007-07-16 2020-08-07 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
CN107254517A (zh) 2008-01-18 2017-10-17 哈佛大学校长及研究员协会 在体液中检测疾病或病症标志的方法
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EA024492B1 (ru) * 2008-07-17 2016-09-30 Новартис Аг Антитела, специфически связывающиеся с baffr, и их применение
US20100098730A1 (en) 2008-10-14 2010-04-22 Lowman Henry B Immunoglobulin variants and uses thereof
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
KR101812811B1 (ko) 2008-12-23 2017-12-27 제넨테크, 인크. 단백질 ａ에 대해 변경된 결합을 갖는 이뮤노글로불린 변이체
AR075896A1 (es) 2009-03-20 2011-05-04 Genentech Inc Anticuerpos anti-her (factor de crecimiento epidermico)
MX2012002909A (es) 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
MX342250B (es) 2009-09-30 2016-09-22 Genentech Inc Tratamiento de cánceres resistentes a antagonistas notch1, mediante el uso de antagonistas notch3.
WO2011071577A1 (en) 2009-12-11 2011-06-16 Genentech, Inc. Anti-vegf-c antibodies and methods using same
US20110171231A1 (en) * 2010-01-12 2011-07-14 Carlos Bais ANTI-PlGF ANTIBODIES AND METHODS USING SAME
MY197016A (en) 2010-02-24 2023-05-20 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
TWI667257B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
CN101851278B (zh) * 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
KR20130041962A (ko) 2010-07-23 2013-04-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 식작용 세포를 사용하여 질환 또는 상태를 검출하는 방법
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
EP2596117B1 (en) 2010-07-23 2017-12-27 President and Fellows of Harvard College Methods of detecting kidney-associated diseases or conditions
EA201390150A1 (ru) 2010-07-23 2013-09-30 Президент Энд Феллоуз Оф Гарвард Колледж Способы выявления сигнатур заболевания или патологических состояний в текучих средах организма
US9963504B2 (en) 2010-09-02 2018-05-08 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
US9458240B2 (en) 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
PH12013501435B1 (en) 2011-01-14 2019-02-01 UCB Biopharma SRL Antibody molecules which bind il-17a and il-17f
PT2694106T (pt) 2011-04-01 2018-03-05 Immunogen Inc Métodos para aumentar eficácia de terapia de cancro de folr1
US9867886B2 (en) * 2011-04-15 2018-01-16 Snu R&Db Foundation Complex in which anti-cotinine antibody is bound to conjugate of cotinine and binding substance, and use thereof
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
BR112014008212A2 (pt) 2011-10-05 2017-06-13 Genentech Inc método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
JP6193275B2 (ja) 2012-03-02 2017-09-06 ヴァクシネックス， インコーポレイテッド Ｂ細胞媒介炎症性疾患を治療するための方法
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
WO2014036520A1 (en) 2012-08-30 2014-03-06 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
SG10201804260QA (en) 2012-08-31 2018-07-30 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
HK1213009A1 (zh) * 2012-11-13 2016-06-24 F. Hoffmann-La Roche Ag 抗原特异性浆母细胞的富集
CN105408355A (zh) 2013-01-31 2016-03-16 瓦克纳斯有限公司 用于提高免疫球蛋白a水平的方法
WO2014164366A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting cancer
US11585814B2 (en) 2013-03-09 2023-02-21 Immunis.Ai, Inc. Methods of detecting prostate cancer
EP2968540A2 (en) 2013-03-14 2016-01-20 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
EP2983710B1 (en) 2013-04-09 2019-07-31 Annexon, Inc. Methods of treatment for neuromyelitis optica
EP4252769A3 (en) 2013-07-09 2023-11-29 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
JP2016536330A (ja) 2013-08-30 2016-11-24 イミュノジェン， インコーポレイテッド 葉酸受容体１の検出用の抗体及びアッセイ
WO2015100246A1 (en) 2013-12-24 2015-07-02 Ossianix, Inc. Baff selective binding compounds and related methods
CA3090240A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
MA40636A (fr) 2014-09-11 2015-09-11 Colleen Kelly Procédés pour détecter le cancer de la prostate
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
EP3215527B1 (en) 2014-11-05 2025-01-08 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
WO2016164637A1 (en) 2015-04-07 2016-10-13 Alector Llc Anti-sortilin antibodies and methods of use thereof
RU2759949C2 (ru) * 2015-05-01 2021-11-19 Инхибркс, Инк. Молекулы, нацеленные на систему секреции типа iii
CN116063499A (zh) 2015-06-12 2023-05-05 艾利妥 抗cd33抗体及其使用方法
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
SI3322734T1 (sl) 2015-07-16 2021-02-26 Inhibrx, Inc. Multivalentni in multispecifični DR5-vezavni fuzijski proteini
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
CN117069841A (zh) 2015-10-06 2023-11-17 艾利妥 抗trem2抗体及其使用方法
EP3368575B1 (en) 2015-10-29 2025-05-07 Alector LLC Anti-siglec-9 antibodies and methods of use thereof
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
US11136405B2 (en) * 2016-06-06 2021-10-05 Board Of Regents, The Unviersity Of Texas System BAFF-R antibodies and uses thereof
KR102356864B1 (ko) * 2016-06-06 2022-02-04 시티 오브 호프 Baff-r 표적 키메라 항원 수용체-변형된 t 세포 및 그 용도
CN117024560A (zh) 2016-12-22 2023-11-10 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
KR102733407B1 (ko) 2017-08-03 2024-11-21 알렉터 엘엘씨 항-cd33 항체 및 이의 이용 방법
BR112019022752A2 (pt) 2017-08-03 2020-05-19 Alector Llc anticorpos anti-trem2 e métodos de uso dos mesmos
ES2873650T3 (es) 2017-09-19 2021-11-03 Tillotts Pharma Ag Variantes de anticuerpos
ES2978167T3 (es) 2017-09-19 2024-09-06 Tillotts Pharma Ag Variantes de anticuerpos
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP3456738B1 (en) 2017-09-19 2024-07-17 Tillotts Pharma Ag Antibody variants
KR20250020681A (ko) 2017-10-10 2025-02-11 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
EP3625263B8 (en) 2017-10-27 2025-05-28 New York University Anti-galectin-9 antibodies and uses thereof
SG11202006148UA (en) 2018-01-03 2020-07-29 Alpine Immune Sciences Inc Multi-domain immunomodulatory proteins and methods of use thereof
PE20210342A1 (es) 2018-05-25 2021-02-23 Alector Llc Anticuerpos anti-sirpa y metodos de utilizacion de los mismos
EP3801767A1 (en) 2018-06-08 2021-04-14 Alector LLC Anti-siglec-7 antibodies and methods of use thereof
MX2019012869A (es) 2018-07-13 2020-01-23 Alector Llc Anticuerpos anti-sortilina y metodos para su uso.
MX2021000933A (es) 2018-07-27 2021-05-27 Alector Llc Anticuerpos anti-siglec-5 y métodos para su uso.
US12247073B2 (en) 2018-08-31 2025-03-11 Alector Llc Anti-CD33 antibodies and methods of use thereof
US20200140533A1 (en) 2018-11-02 2020-05-07 Annexon, Inc. Compositions and methods for treating brain injury
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2020154889A1 (zh) * 2019-01-29 2020-08-06 上海鑫湾生物科技有限公司 具有Fc突变体的抗体与效应细胞的组合、用途和制法
US20220178930A1 (en) * 2019-05-01 2022-06-09 New York University Anti-galectin-9 antibodies and uses thereof
US12023354B2 (en) 2019-05-31 2024-07-02 Case Western Reserve University Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells
US20230024528A1 (en) 2019-12-05 2023-01-26 Alector Llc Methods of use of anti-trem2 antibodies
EP4073119A1 (en) 2019-12-12 2022-10-19 Alector LLC Methods of use of anti-cd33 antibodies
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
MX2022011752A (es) 2020-03-24 2022-10-18 Genentech Inc Agentes de fijacion a tie2 y metodos de uso.
US20230183341A1 (en) 2020-04-03 2023-06-15 Alector Llc Methods of use of anti-trem2 antibodies
CA3178882A1 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins and methods of use thereof
CA3169949A1 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4192870A1 (en) * 2020-08-04 2023-06-14 Novartis AG Treatment of cll
CN112999346A (zh) * 2021-03-04 2021-06-22 华中科技大学同济医学院附属协和医院 Baff抗体在制备治疗炎症性肠病药物中的应用
MX2024003913A (es) * 2021-09-29 2024-04-26 Dragonfly Therapeutics Inc Anticuerpos dirigidos al receptor del factor activador de celulas b (baff-r) y uso de los mismos.
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
CA3243760A1 (en) 2022-02-23 2023-08-31 Alector Llc METHODS OF USING ANTI-TREM2 ANTIBODY

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
MX353234B (es) * 1999-01-15 2018-01-08 Genentech Inc Variantes de polipeptidos con función efectora alterada.
UA83458C2 (ru) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Выделенный полипептид baff-r (рецептор фактора активации в-клеток семейства tnf)
KR20040019105A (ko) * 2001-08-03 2004-03-04 제넨테크, 인크. ＴＡＣＩｓ 및 ＢＲ3 폴리펩티드 및 이의 용도
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization

Also Published As

Publication number Publication date
JP2008526205A (ja) 2008-07-24
US20080181888A1 (en) 2008-07-31
BRPI0518994A2 (pt) 2008-12-02
AU2005323025A1 (en) 2006-07-13
NO20072721L (no) 2007-10-01
CN101120021A (zh) 2008-02-06
AP2007004034A0 (en) 2007-06-30
WO2006073941A9 (en) 2007-07-05
MX2007008017A (es) 2007-09-12
IL183353A0 (en) 2008-04-13
US20100280227A1 (en) 2010-11-04
KR20070107687A (ko) 2007-11-07
WO2006073941A2 (en) 2006-07-13
EP1838735A2 (en) 2007-10-03
WO2006073941A3 (en) 2006-08-31
CA2595112A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
EA200701211A1 (ru) Полипептиды, которые связываются с br3, и их применение
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
EA201170312A1 (ru) Селективные антитела к гепцидину-25 и их применение
MA32982B1 (fr) Proteines de liaison au recepteur cgrp humain
EA201290570A1 (ru) Конструкты, связывающиеся с ron, и способы их использования
EA201100694A1 (ru) Антитело к cd38 человека и его применение
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
RU2599417C3 (ru) Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
EA201190041A1 (ru) Человеческие аутоантитела против альфа-синуклеина
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
MY174493A (en) Binding agents
EA200701448A1 (ru) Специфически связывающаяся с крипто-антигеном человека молекула (варианты), композиция на ее основе (варианты), способ получения молекулы, способ лечения посредством молекулы (варианты) и способ ингибирования крипто-экспрессии в клетке больного
MX2008009886A (es) Anticuerpos que enlazan par-2.
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
DE502005009389D1 (de) Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
BR112021018632A2 (pt) Moléculas de ligação ao cd3
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
EP2083018A3 (en) Compositions and methods relating to STOP-1
DE602006013143D1 (de) Verfahren zum nachweis aggregatbildender zirkulierender proteinformen und mittel zum einfangen gebildeter aggregate
WO2005094159A3 (en) Methods of identifying neoplasm-specific antibodies and uses thereof
TW200718711A (en) Polypeptides that bind BR3 and uses thereof